“PolyPeptide delivered 23.7% revenue growth in H1 2025, driven mainly by growth in metabolic therapeutics, and an increase in commercial revenue by 37.9%; we revised our 2025 full-year guidance towards the upper end of the range and confirm our mid-term outlook.”